BriaCell entered a manufacturing arrangement with FUJIFILM Biotechnologies California to support production of its Bria-IMT cell therapy.
The deal secures capacity for the remainder of the pivotal Phase 3 metastatic breast cancer study, supporting Bria-IMT with an immune checkpoint inhibitor.
The agreement also provides a path to scale manufacturing for potential commercial supply.
BCTX•
